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Tbjective: Air leakage is a frequent complication during lung surgery. A new hydrogel
lue was created by mixing aldehyded dextran and -poly(l-lysine), and its feasibility as
surgical sealant was evaluated in comparison with that of conventional fibrin glue.
ethods: Bursting pressure after application of each glue to 30  30-mm pleuro-
arenchymal defects was evaluated in two groups of 14 beagle dogs. Biodegrad-
bility and histotoxicity of the glues were evaluated in another 6 dogs with 15-mm
ircular pleuroparenchymal defects. Adhesions, infections, and histologic changes
ere observed on scheduled days for 6 months.
esults: The mean bursting pressure after application was 38.4  4.6 cm H2O for
he new glue and 32.1 4.5 cm H2O for fibrin glue (P .02), the former providing
ore effective sealing of pulmonary air leakage than the latter. Macroscopically, no
dhesions or infections were observed in areas of glue application. About 90% of the
ew glue degraded within 3 months, but complete disappearance was not observed
y 6 months. On the other hand, the fibrin glue was replaced by white pleural tissue
t 4 weeks. Histologically, the new glue was covered by one layer of mesothelial
ells at 2 weeks and completely covered by thick fibrous tissue at 4 weeks.
nflammatory reaction was minimal around the residual glue after 3 months.
lthough the new glue degraded more slowly than did the fibrin glue, the biocom-
atibility of the new glue was sufficient for clinical use.
onclusion: Our new hydrogel glue demonstrates a strong sealing effect, with good
iocompatibility, and has potential usefulness as an adhesive in lung surgery.
ostoperative air leakage is the most frequent complication after lung surgery.
Although it is usually not life-threatening, management of air leakage re-
quires chest tube drainage, necessitating longer hospitalization. Standard
urgical methods using sutures or staples have a disadvantage of causing further
rauma to the lung tissue. Therefore, various tissue sealants have been applied to
revent air leakage after lung surgery.1-5
Among these sealants, fibrin glue is widely used. Various application techniques
ave been developed to enhance the adhesive properties of fibrin glue, such as
ubbing and spraying, which enhance the sealing effect.6,7 However, some reports
ave indicated that the use of fibrin glue does not reduce the duration of chest-tube
rainage or hospitalization.8,9 In fact, thoracic surgeons have often found that the
he Journal of Thoracic and Cardiovascular Surgery ● Volume 134, Number 5 1241
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1
ETse of fibrin glue alone often fails to prevent air leakage
rom pulmonary parenchymal defects during surgery and
hat postoperative leakage tends to recur. Furthermore, the
ndustrial production of fibrin glue has an inherent disad-
antage in that the basic source material is human blood,
nd thus complete prevention of infectious contamination is
ifficult. Therefore, new synthetic sealants have been de-
eloped and their efficacy has been investigated in animal
odels.10-18
Recently, a new biodegradable hydrogel glue (new-glue)
as developed, and its favorable properties as a sealant
ere reported.19 New-glue comprises two aqueous solutions
f aldehyded dextran and -poly(l-lysine). After the two
olutions have been mixed, gel formation proceeds on the
asis of Schiff base formation. In the body, new-glue is
egraded mainly by hydrolysis. It has a number of favorable
haracteristics, such as high bonding strength, high flexibil-
ty, and low cytotoxicity. Furthermore, the onset time of gel
ormation and the in vitro degradation speed of the hydrogel
an be controlled arbitrarily by variation of the selected
Figure 1. Chemical structure and appearance of new-g
dextran and -poly(l-lysine) (A). After the two solution
base formation. An equal volume of each solution is s
4°C until use (B).omponents. a
242 The Journal of Thoracic and Cardiovascular Surgery ● NovThe aim of this study was to evaluate the efficacy of the
ew synthetic hydrogel glue when applied to pulmonary
issue. The sealing effect of new-glue was evaluated by
easuring the air leakage pressure in pleuroparenchymal
efect models in comparison with that of conventional fibrin
lue. In addition, in vivo degradability and histotoxicity
ere examined for assessment of biocompatibility.
aterials and Methods
reparation of new-glue
ew-glue is a hydrogel adhesive prepared by mixing two kinds of
iquid of aldehyded polysaccharide and -poly(l-lysine), which
orm a Schiff base.19 The chemical structure and crosslinking are
escribed in Figure 1, A. In brief, solution A is composed of 20
/w% aldehyded dextran with a molecular weight of 75K. The
ldehyde groups are introduced by conventional periodate oxida-
ion of dextran (Malaprade oxidation). Solution B is composed of
0 w/w% -poly(l-lysine) with a molecular weight of 4K contain-
ng 2 w/w% succinic anhydride. Solution B is dyed blue (brilliant
lue FCF; Wako Pure Chemical Industries, Ltd, Osaka, Japan) at
concentration of 50 ppm for visualization. After sterilization with
New-glue is composed of two solutions of aldehyded
mixed, gel formation proceeds on the basis of Schiff
in the separate cylinders of a dual syringe device atlue.
s are
toredsyringe filter (0.2-m pore size), 2 mL of each solution is stored
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ETn each cylinder of a dual-syringe device (Mini-Dual Syringe;
las-Pak Industries, Inc, Norwich, Conn) at 4°C until use (Figure
, B). The onset time and end time of gel formation at 25°C are
bout 10 and 60 seconds, respectively.
nimals and Anesthesia
he Kyoto University Animal Experimentation Committee ap-
roved the experiment, and all the surgical procedures and eutha-
asia were performed in accordance with the National Institutes of
ealth animal care guidelines. Twenty adult beagle dogs weighing
pproximately 8.0 to 12.0 kg were used for this study. After
remedication with atropine sulfate at 0.03 mg/kg, the dogs were
nesthetized by intramuscular injection of ketamine hydrochloride
t 15 mg/kg and xylazine at 7 mg/kg. After intratracheal intubation
ith a Broncho-Cath endobronchial tube (Mallinckrodt Medical,
t Louis, Mo) for 1-lung ventilation, mechanical ventilation at a
espiratory rate of 14 breaths/min and a tidal volume of 25 mL/kg
as started (50% oxygen, 50% nitrous oxide mixed with 1%
alothane) to allow maintenance of anesthesia by inhalation during
urgery. The airway pressure was sustained at 10 to15 cm H2O.
uring 1-lung ventilation, tidal volume was maintained so that it
id not exceed an airway pressure of 15 cm H2O. Ampicillin
odium at 50 mg/kg was administered intravenously just before the
peration.
ssessment of Sealing Effect of the Glues
ourteen beagle dogs were used as subjects to evaluate the sealing
ffect of the glues. The animals were placed in the left decubitus
osition, and a right thoracotomy was performed. A pleuroparen-
hymal defect was created in the upper lobe with scalpels and
lectrocautery for hemostasis (coagulation 60 W, ACUTOR SK-2,
coma Medical Industry Co, Ltd, Tokyo, Japan), with the lung
ully inflated at a positive airway pressure of 15 cm H2O. The
efect size was adjusted to be 30  30-mm square and 1-mm deep
Figure 2, A). The lung was immersed in normal saline solution,
nd the air leakage pressure at which bubbles first formed was
easured. The following two methods were used to compare the
ealing effect of the glue after application.
Rubbing of new-glue (7 dogs). New-glue (0.1 mL/cm2) was
ropped onto the pleuroparenchymal defect area and rubbed gently
or 10 seconds. After application, the glue surfaces were kept at
est by 1-lung ventilation for 2 minutes.
Rubbing and spraying of fibrin glue (7 dogs). The fibrin glue
sed in this study was a commercially available type (Bolheal; h
The Journal of Thoracichemo-Sero-Therapeutic Research Institute, Kumamoto, Japan).
his fibrin glue consists of two components. Solution A is a protein
oncentrate consisting of fibrinogen, plasma fibronectin, factor VIII,
nd plasminogen, reconstituted in aprotinin solution. Solution B is
hrombin reconstituted in calcium chloride solution. For the rubbing
nd spraying method,6,7 solution A was dripped and gently rubbed
nto the pleuroparenchymal defect area. Then, both solutions (0.2
L/cm2) were sprayed simultaneously onto the rubbed surface as a
ixed aerosol using a Bolheal spray set (Chemo-Sero-Therapeutic
esearch Institute). After application, the glue surfaces were kept at
est with 1-lung ventilation for 5 minutes.
The lung was again inflated after immersion in normal saline
olution, and airway pressure was monitored. The airway pres-
ure at which onset of air leakage was confirmed by observation
f bubbles was defined as the bursting pressure in this study.
hen major air leakage in the sealing area was still observed at
5 cm H2O because of destruction of the sealant after the air
eakage test, the glue was reapplied. After these procedures, the
horacic cavity was thoroughly lavaged, a 10F chest tube was
laced, the wound was closed in layers, and the animals were
llowed to recover. The chest tube was intermittently monitored
or air and fluid output until disappearance of air leakage.
horacic radiographs were taken at 3 days and 1, 2, 4, 8, 12, 16,
0, and 24 weeks after the operation to evaluate the inflation of
he lung. The animals were humanely killed by intravenous
dministration of an overdose of pentobarbital 1, 2, 4, 8, 12, 16,
nd 24 weeks after the operation for gross observation of
dhesion and infection.
ssessment of Glue Biodegradability and Histotoxicity
nother group of 6 beagle dogs was used to evaluate the biode-
radability and histotoxicity of the glues. After thoracotomy, two
ircular pleuroparenchymal defects with a diameter of 15 mm were
reated in the upper lobe of the right lung (Figure 2, B). Each site
as resected with scalpels, and hemostasis was obtained by pres-
ure with a sponge to avoid a thermal injury caused by electro-
autery.20 Each pleuroparenchymal defect was sealed by new-glue
r fibrin glue as in the previous technique. After these procedures,
he chest was closed in layers, and the dogs were allowed to
ecover, except for 1 dog that was used to evaluate the penetration
f the glues after application. The animals were humanely killed
y intravenous administration of an overdose of pentobarbital 1
Figure 2. Pleuroparenchymal defects for
evaluation of glue sealing effect and his-
totoxicity. Large pleuroparenchymal de-
fects (30  30-mm square, 1-mm deep)
were created with scalpels and electro-
cautery for the evaluation of sealing ef-
fect (A). Circular pleuroparenchymal de-
fects (15 mm in diameter) were created
with scalpels, and hemostasis was ob-
tained by pressure with a sponge for
evaluation of histotoxicity (B).our after application and 2, 4, 8, 12, and 24 weeks after the
and Cardiovascular Surgery ● Volume 134, Number 5 1243
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1
ETperation to evaluate the biodegradability and histotoxicity of the
lues.
The whole right lungs were reinflated with 10% formalin and
mmersed in the same solution. After fixation, each defect site was
esected, embedded in paraffin, sectioned, and subjected to hema-
oxylin and eosin, Masson trichrome, and elastica–van Gieson
taining.
tatistical Analyses
he data shown represent mean values  standard deviation. The
npaired t test was used to compare different treatments and
etermine the P value.
esults
hroughout the experiment, all the animals survived un-
ventfully until they were humanely killed, and there was no
hange in body weight exceeding 1 kg.
ealing Effect of the Glues
he mean air leakage pressure after creation of the pleuro-
arenchymal defects was 7.7  0.9 cm H2O for the new-
lue animals and 8.1  0.7 cm H2O for the fibrin glue
nimals, the intergroup difference being nonsignificant
P  .82). Severe air leakage was observed at 15 cm H2O
rom the whole of the resected area in all animals. The mean
ursting pressure after application of the glues was 38.4 
.6 cm H2O for new-glue and 32.1  4.5 cm H2O for fibrin
lue (Figure 3). New-glue showed better sealing effect
han that of fibrin glue (P  .02). Three animals treated
ith fibrin glue underwent glue reapplication because
ost of the glues had peeled off during lung inflation. In
igure 3. Bursting pressure before and after application of new-
lue and fibrin glue. There were no significant differences in
ean air leakage pressure after creating the pleuroparenchymal
efects (P  .82). After application, new-glue showed better
ealing effect than fibrin glue (P  .02).ll animals, it was possible to remove the chest tube on t
244 The Journal of Thoracic and Cardiovascular Surgery ● Novhe day after the operation, and chest radiographs showed
nflation of the lung on each scheduled day. Macroscop-
cally, severe adhesion of the right whole lung was ob-
erved in 1 animal treated with each glue, resulting from
njury of the intercostal arteries during chest tube inser-
ion. Except in these 2 animals, no adhesions or infec-
ions were observed in the areas of glue application.
acroscopic Observations of Glue Biodegradability
n the 6 animals used for assessment of glue biodegradabil-
ty and histotoxicity, no adhesions or infections were ob-
erved in the application area for both new-glue and fibrin
lue. Macroscopically, new-glue was dyed brown, owing to
he Maillard reaction, and was covered by a thin white
embrane at 2 weeks after the operation (Figure 4, C). It
as still clearly present and transparent at 4 weeks (Figure
, E) but was considerably lightened at 2 months (Figure 5,
). About 90% of the new-glue degraded within 3 months,
ut some scattered residual glue was still obvious (Figure 5,
). Degradation of new-glue had progressed further by 6
onths, but complete disappearance was not observed at
his time (Figure 5, E). On the other hand, a small amount
f whitish fibrin glue was obviously present at the center of
he application area at 2 weeks (Figure 6, C). At 4 weeks,
he application area was covered by whitish colored pleura
Figure 6, E). After 2 months, it was difficult to distinguish
he application area from the surrounding normal pleura,
xcept for the presence of a hollow.
istologic Study of Glue Biodegradability and Histotoxicity
istologically, new-glue had penetrated into the lung pa-
enchyma to a depth of about 400 m at 1 hour after
pplication (Figure 4, B). At 2 weeks, new-glue was covered
y one layer of mesothelial cells. Infiltration of foreign body
iant cells, lymphocytes, and fibroblasts was observed
round the glue. No necrotic tissue or hemorrhage was
vident (Figure 4, D). At 4 weeks, new-glue was completely
overed by thick fibrous tissue with decreased numbers of
istiocytes and fibroblasts and an increased amount of col-
agen fibers (Figure 4, F). Degradation of new-glue had
rogressed further by 2 months (Figure 5, B), and the glue
ad mostly disappeared from the lung surface by 3 months
Figure 5, D). At 6 months, there was no inflammatory
eaction around the small amount of residual glue and no
brotic change in the regenerated pleura and lung paren-
hyma (Figure 5, F). On the other hand, fibrin glue had
enetrated into the lung parenchyma to a depth of about
00 m at 1 hour after application (Figure 6, B) and at 2
eeks was encapsulated by a thick fibrocellular layer.
nfiltration of histiocytes, lymphocytes, and fibroblasts
as observed around the glue (Figure 6, D). At 4 weeks,
he application area had been replaced by thick fibrous
issue with slight infiltration of lymphocytes (Figure 6,
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ET). After 2 months, the lung surface was completely
overed by a thick fibrocellular layer, which gradually
hinned within 6 months.
iscussion
ealant materials for preventing air leakage must be suffi-
iently strong to remain sealed when the lung is inflated to
ressures of up to 30 to 40 cm H2O.5 For a sealant spread on
ulmonary tissue, flexibility and compliance are desirable
ualities to accommodate the physiologic expansion and
ontraction of the lung. Such a material should also bond
apidly to the lung tissue and remain unaltered by underly-
ng blood or moisture. Furthermore, the sealant should be
ocally nonirritating, systemically nontoxic, lacking in an-
igenicity, bacteriostatic, and slowly soluble in body fluids.
lthough fibrin glue has been widely used, it carries a risk
f virus infections. It has been reported that more than 20%
f uninfected persons become infected with human parvo-
irus B19 through the use of fibrin sealant during thoracic
urgery.21 Therefore, it has been recommended that the use
f fibrin glue should be limited to healthy adults for whom
t is inevitably required until human parvovirus B19–free
roducts become clinically available. c
The Journal of ThoracicThis is the first report of the use of a newly developed
ydrogel glue in vivo. Nakajima and associates19 have
eported some favorable properties of new-glue as a tissue
dhesive for medical applications. New-glue has no risk of
ransmitting infectious materials of human or animal origin,
ecause human plasma and animal-derived components are
ot used as its source. It is biodegradable and ready to use
ecause no dissolution time is required. Furthermore, it has
igh flexibility and a bonding strength 4 times higher than
hat of fibrin glue. Although necrotic changes in the lung
arenchyma after the use of gelatin resorcinol–formaldehyde–
lutaraldehyde glue4 have been reported, the cytotoxicity of
ldehyded dextran and -poly(l-lysine) is about 1/1500 that of
ormaldehyde or glutaraldehyde, or less.
In this study, new-glue was recognized to possess some
esirable properties as a lung sealant. First, its bursting
ressure was significantly higher than that of fibrin glue
hen applied by rubbing and spraying. Previous experimen-
al studies documenting the effectiveness of fibrin glue and
ther tissue adhesives for sealing air leakages were per-
ormed on relatively small pulmonary defects.4,5,10-16 Clin-
cally, however, large pleuroparenchymal defects are often
Figure 4. Macroscopic and histologic
appearance at 1 hour and 2 and 4
weeks after application of new-glue.
New-glue, which was dyed blue, was
rubbed on the defect area (A) and pen-
etrated into the deep lung parenchyma
(B). At 2 weeks, the glue had turned
brown, owing to the Maillard reaction,
and was covered by a thin white mem-
brane (C), consisting of one layer of
mesothelial cells. Foreign body giant
cells and fibroblasts were observed
around the glue (D). At 4 weeks, the
glue was still evident (E) and was
completely covered by thick fibrous
tissue (F) (hematoxylin and eosin stain;
original magnification  100; scale bar
shows 200 m).reated by segmentectomy, synechotomy, or interlobar tran-
and Cardiovascular Surgery ● Volume 134, Number 5 1245
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1
ETection. The mean air leakage pressure of 38.4 cm H2O used
n our large pleuroparenchymal defect model would be
ithin the range of the increase in airway pressure caused
y coughing. Furthermore, the appearance of seal breakage
as pinhole-like for new-glue but extensive for fibrin glue.
ibrin glue often peels off after the lung is inflated because
f its low bonding strength and low flexibility. The use of
ew-glue would shorten the period of chest tube drainage.
econd, the time required for onset of new-glue gel forma-
ion was about 10 seconds, which allowed sufficient time to
ub the glue into the surface of the lung parenchyma. This
s in contrast to the immediate gel formation by fibrin glue,
aking it impossible to rub the mixed solutions into the
ung surface. Third, new-glue had sufficient flexibility,
hich is an indispensable characteristic for a lung sealant.
ourth, neither adhesion nor infection was observed around
reas where new-glue had been applied.
Previously, we had adopted another conventional animal
leuroparenchymal defect model to evaluate the biodegrad-
bility and histotoxicity of glues. However, this model had two
ajor problems. First, the glues, especially fibrin glue, peeled
ff during measurement of the seal breaking pressure. Reap-
lication of the glues for air sealing led to an increased glue
olume, making it difficult to evaluate the biodegradability of w
246 The Journal of Thoracic and Cardiovascular Surgery ● Novhe glues accurately. Therefore, we used separate animal mod-
ls for measurement of bursting pressure and for evaluation of
lue biodegradability. Second, thermal injury caused by elec-
rocautery for hemostasis, such as destruction of alveoli and
evere infiltration of fibroblasts in the lung parenchyma, was
nevitable, making it difficult to evaluate the histotoxicity of
he glues accurately. To overcome these problems, we20 estab-
ished a new method for creating a uniform pleural defect
odel for studies of lung sealants, and we applied this animal
odel in the present experiment to evaluate the histotoxicity of
he glues.
Histologically, penetration of new-glue into the lung
arenchyma was almost equivalent to that of fibrin glue.
ne layer of mesothelial cells covered new-glue by 2
eeks. Infiltration of inflammatory cells around the glue
as more than that around fibrin glue. Inflammatory reac-
ions were reduced by 4 weeks, and about 90% of new-glue
ad degraded on the lung surface by 3 months after appli-
ation. The normal structure of the pleura and lung paren-
hyma had recovered by 6 months. Fibrin glue, on the other
and, showed rapid degradation and had completely disap-
eared by 4 weeks.
The histologic findings indicated that air leakage
Figure 5. Macroscopic and histologic
appearance 2, 3, and 6 months after
application of new-glue. At 2 months,
new-glue had considerably lightened
(A), and inflammatory reactions around
it were slight (B). At 3 months, about
90% of the glue had degraded (C), and
scattered fragments of residual glue
were evident (D). By 6 months, com-
plete disappearance of the glue had
not occurred (E), and no inflammatory
reaction was observed around the
slight amount of residual glue (F) (he-
matoxylin and eosin stain; original
magnification  100; scale bar shows
200 m).ould not recur after 4 weeks, because by that time
ember 2007
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ETew-glue or fibrin glue had been completely covered by
hick fibrous tissue. Therefore, absorption of a lung seal-
nt by tissues after 4 weeks may be desirable, because
ny remnant material might induce an unfavorable for-
ign body reaction such as inflammation or infection. An
n vitro experiment showed that new-glue was degraded
n phosphate-buffered saline within about 4 weeks.19
owever, new-glue did not disappear completely from
he lung surface until 6 months after application, even
hough it had become covered by one layer of mesothelial
ells by 2 weeks. Differences in the fluid environment
urrounding the glue might influence the rate of bioab-
orption. However, new-glue seemed to have sufficient
iocompatibility for clinical use during the absorption
rocess, because there was only a minimal inflammatory
eaction around the area of application.
onclusions
ur new biodegradable hydrogel glue had sufficient sealing
roperties for preventing air leakage from large pleuroparen-
hymal defects. New-glue was significantly superior to fibrin
lue as a sealant in this beagle model. It showed slower in vivo
egradation and a slightly more inflammatory reaction in the
arly stage than did fibrin glue, although the normal lung
The Journal of Thoracictructure had recovered without fibrosis by 6 months. We
elieve that new-glue may be an alternative to fibrin glue for
he control of air leakage during lung surgery.
We thank Nobuhisa Yonemitsu from the Department of Pathol-
gy, Sasebo Chuou Hospital, for his assistance in the assessment
f glue histotoxicity.
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